The ongoing Corona pandemic that affects Sweden and the rest of the world has a major impact on all parts of society and has had far-reaching effects on businesses around the world. AroCell is affected to a relatively limited extent. The internal operations continue to be uninterruptedly driven forward and important steps are taken for preparation for continued dialogue with the FDA. Some meetings and conferences have been cancelled or postponed, which means that we are reviewing our plan for publishing clinical data. Otherwise, Corona pandemic impact on AroCell is limited. The value of the company is based, among other things, on future sales and how AroCell in the future can contribute to better care for cancer patients. AroCell continues to work with the goal of getting our AroCell TK 210 ELISA approved by the FDA in the United States by 2021. Until then, we will have limited sales on the U.S. market.
"As a company, our share price is highly effected by what is happening in the stock market right now but if we look at fundamentals we are hardly affected at all. We have digital meetings that replace physical meetings and continue our business of developing collaborations and contacts with oncologists", says Michael Brobjer, AroCells CEO.